Agentix Corp. (AGTX)

Overview

Agentix Corp. is at the clinical development stage, focusing its efforts on the innovation of novel therapeutic solutions aimed at treating metabolic diseases. The company transitioned from its original identity, FairWind Energy, Inc., to Agentix Corp. in June 2019, signaling a strategic pivot towards the biopharmaceutical sector. Founded in 2020 and operating out of Dana Point, California, Agentix Corp. is dedicated to advancing its proprietary drug candidates through rigorous clinical trials to eventually bring them to market.

Products and Services

• AGTX-2004: A peripherally-acting CB1 receptor antagonist, AGTX-2004 represents a promising therapeutic candidate for tackling obesity and type 2 diabetes mellitus. By inhibiting the CB1 receptor peripherally, this compound has shown significant potential in animal models, indicating its efficacy in reducing obesity-related metabolic parameters and improving glycemic control. The development of AGTX-2004 underscores Agentix Corp.'s commitment to addressing the growing global health challenges posed by obesity and diabetes.

• AGTX-2003: This compound is a peripherally-acting CB1 receptor inverse agonist, which has demonstrated impressive efficacy in animal models for obesity and non-alcoholic fatty liver disease (NAFLD). Like AGTX-2004, AGTX-2003 targets the CB1 receptor but operates through a distinct mechanism of action, potentially offering a novel therapeutic approach for patients struggling with obesity and its related metabolic disorders, including NAFLD. The development of AGTX-2003 aligns with the company’s focus on innovative treatments that address unmet medical needs in metabolic diseases.